Sanofi (SNY) has released an update.
Sanofi has teamed up with Orano Med to invest in developing next-generation radioligand therapies for rare cancers, utilizing lead-212 alpha-emitting isotopes. This collaboration aims to enhance precision medicine by targeting cancer cells while minimizing harm to healthy cells, signaling a significant step in cancer treatment innovation. Sanofi’s €300 million investment underscores its commitment to advancing transformative therapies and strengthening its oncology pipeline.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.